Filing Details

Accession Number:
0001056807-13-000004
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-06-11 17:55:28
Reporting Period:
2013-06-07
Filing Date:
2013-06-11
Accepted Time:
2013-06-11 17:55:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1034842 Rigel Pharmaceuticals Inc RIGL Pharmaceutical Preparations (2834) 943248524
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
918923 P L Fund Value Biotechnology C/O Grosvenor Capital Management Lp
900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No No Yes
1055947 P/Il L Partners Bvf C/O Grosvenor Capital Management Lp
900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No Yes No
1056807 Bvf Inc/Il C/O Grosvenor Capital Management Lp
900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No Yes No
1102444 Biotechnology Value Fund Ii Lp C/O Grosvenor Capital Management Lp
900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No No Yes
1132245 Bvf Investments Llc C/O Grosvenor Capital Management Lp
900 N. Michigan Ave., Suite 1100
Chicago IL 60611
No No No Yes
1233840 N Mark Lampert One Sansome Street, 31St Floor
San Francisco CA 94104
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-06-07 24,598 $3.47 1,455,414 No 4 P Indirect See Explanation of Responses
Common Stock Acquisiton 2013-06-07 8,102 $3.47 799,615 No 4 P Indirect See Explanation of Responses
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Explanation of Responses
No 4 P Indirect See Explanation of Responses
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 6,962,123 Indirect See Explanation of Responses
Footnotes
  1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), BVF Investments, L.L.C. ("BVLLC"), BVF Partners L.P. ("Partners"), BVF Inc., and Mark Lampert (collectively the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a section 13G group that collectively owns more than 10% of the Issuer's oustanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein.
  2. Represents shares of Common Stock owned directly by BVF. As the general partner of BVF, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF.
  3. Represents shares of Common Stock owned directly by BVF2. As the general partner of BVF2, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVF2.
  4. Represents shares of Common Stock owned directly by BVLLC. As the manager of BVLLC, Partners may be deemed to beneficially own the shares of Common Stock owned directly by BVLLC. As the investment adviser and general partner of Partners, BVF Inc., may be deemed to beneficially own the shares of Common Stock owned directly by BVLLC. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the shares of Common Stock owned directly by BVLLC.
  5. Pursuant to the operating agreement of BVLLC, Partners is authorized, among other things, to invest the contributed capital of Samana Capital, L.P., the majority member of BVLLC, in the Common Stock and other securities of the Issuer and to vote, exercise or convert and dispose of such securities and is entitled to receive fees based on assets under management and, subject to certain exceptions, allocations based on realized and unrealized gains on such assets.
  6. Units may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request